{
    "clinical_study": {
        "@rank": "3021", 
        "arm_group": [
            {
                "arm_group_label": "MK-5172 25 mg", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "MK-5172 50 mg", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "MK-5172 100 mg", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a study designed to compare the safety and efficacy of 3 different doses of MK-5172\n      combined with pegylated interferon alfa-2b (PegIFN-2b) and ribavirin (RBV) in\n      treatment-na\u00efve participants with genotype 1 (GT1) chronic hepatitis C (CHC). Participants\n      will receive 12 weeks of treatment with MK-5172 combined with PegIFN-2b and RBV, and\n      depending on response at Week 4 may go on to receive an additional 12 weeks of treatment\n      with PegIFN-2b and RBV."
        }, 
        "brief_title": "A Study of Different Doses of MK-5172 Given With Pegylated Interferon Alfa-2b and Ribavirin to Treatment-Na\u00efve Participants With Chronic Hepatitis C (MK-5172-038 AM2)", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "condition": "Chronic Hepatitis C (CHC)", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis, Chronic", 
                "Hepatitis C", 
                "Hepatitis C, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Treatment naive\n\n          -  Chronic, compensated HCV GT 1 infection\n\n          -  Absence (no medical history or physical findings) of ascites, bleeding esophageal\n             varices, hepatic encephalopathy, or other signs or symptoms of advanced liver\n             disease, or cirrhosis\n\n          -  No evidence of cirrhosis or hepatocellular carcinoma by biopsy or noninvasive testing\n             (e.g. FibroScan and/or FibroTest)\n\n          -  Must agree to use two acceptable methods of birth control from at least 2 weeks prior\n             to first dose and continue until at least 6 months after last dose of study drug, or\n             longer if dictated by local regulations\n\n        Exclusion Criteria:\n\n        - Non-GT1 HCV infection, including a mixed GT infection (with a non-GT1) or a\n\n        non-typeable genotype.\n\n          -  Documented to be HIV positive or co-infected with hepatitis B virus\n\n          -  Hepatocellular carcinoma (HCC) or under evaluation for HCC\n\n          -  Participating in or has participated in a study with an investigational compound or\n             device within 30 days of signing informed consent\n\n          -  Diabetic and/or hypertensive with clinically significant ocular examination findings\n\n          -  Current or history of central nervous system (CNS) trauma, seizure disorder, stroke\n             or transient ischemic attack\n\n          -  Chronic pulmonary disease\n\n          -  Current or history of any clinically significant cardiac abnormalities/dysfunction\n\n          -  Active clinical gout within the last year\n\n          -  History of gastric surgery or history of malabsorption disorders\n\n          -  Active or suspected malignancy, or a history of malignancy, within the last 5 years\n             (except adequately treated carcinoma in situ and basal cell carcinoma of the skin)\n\n          -  Pregnant, lactating, expecting to conceive or donate eggs or male participant\n             planning to impregnate or provide sperm donation or with a female partner who is\n             pregnant\n\n          -  Current moderate or severe depression or history of depression associated with\n             hospitalization, electroconvulsive therapy, or severe disruption of daily functions,\n             or suicidal or homicidal ideation and/or attempt, or history of severe psychiatric\n             disorders\n\n          -  Evidence or history of chronic hepatitis not caused by HCV"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "87", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 17, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01710501", 
            "org_study_id": "5172-038", 
            "secondary_id": "2012-003333-42"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "MK-5172 25 mg", 
                    "MK-5172 50 mg", 
                    "MK-5172 100 mg"
                ], 
                "description": "MK-5172 tablet, orally, once per day at assigned dose", 
                "intervention_name": "MK-5172", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "MK-5172 25 mg", 
                    "MK-5172 50 mg", 
                    "MK-5172 100 mg"
                ], 
                "description": "PegIFN-2b, 1.5 mcg/kg/week, subcutaneously (SC)", 
                "intervention_name": "PegIFN-2b", 
                "intervention_type": "Biological", 
                "other_name": [
                    "SCH 054031", 
                    "PegIntron\u2122"
                ]
            }, 
            {
                "arm_group_label": [
                    "MK-5172 25 mg", 
                    "MK-5172 50 mg", 
                    "MK-5172 100 mg"
                ], 
                "description": "Ribavirin capsule, orally, twice daily, at a dose of 800 to 1400 mg based on participant weight", 
                "intervention_name": "Ribavirin", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Rebetol\u2122", 
                    "RBV"
                ]
            }, 
            {
                "arm_group_label": [
                    "MK-5172 25 mg", 
                    "MK-5172 50 mg", 
                    "MK-5172 100 mg"
                ], 
                "description": "Placebo to match MK-5172 tablets to maintain dose blinding", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Ribavirin", 
                "Peginterferon alfa-2b"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 1, 2014", 
        "number_of_arms": "3", 
        "official_title": "A Phase II Randomized, Dose Ranging, Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Different Doses of MK-5172 When Administered Concomitantly With Peginterferon Alfa-2b and Ribavirin in Treatment Na\u00efve Subjects With Chronic Hepatitis C Virus Infection", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Number of subjects achieving Sustained Virologic Response (SVR) at 12 weeks (SVR12) after the end of treatment", 
                "safety_issue": "No", 
                "time_frame": "Up to Week 36"
            }, 
            {
                "measure": "Number of participants experiencing at least one adverse event (AE)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 48 weeks"
            }, 
            {
                "measure": "Number of participants discontinued from study treatment due to AEs", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 24 weeks"
            }
        ], 
        "removed_countries": {
            "country": [
                "United States", 
                "Canada", 
                "New Zealand", 
                "Sweden", 
                "United Kingdom"
            ]
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01710501"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Number of subjects achieving undetectable hepatitis C virus ribonucleic acid (HCV RNA) at Week 2", 
                "safety_issue": "No", 
                "time_frame": "Week 2"
            }, 
            {
                "measure": "Number of subjects achieving undetectable HCV RNA at Week 4", 
                "safety_issue": "No", 
                "time_frame": "Week 4"
            }, 
            {
                "measure": "Number of subjects achieving undetectable HCV RNA at Week 12", 
                "safety_issue": "No", 
                "time_frame": "Week 12"
            }, 
            {
                "measure": "Number of subjects achieving undetectable HCV RNA at Week 24", 
                "safety_issue": "No", 
                "time_frame": "Week 24"
            }, 
            {
                "measure": "Number of participants achieving HCV RNA <25 IU/mL at Week 2", 
                "safety_issue": "No", 
                "time_frame": "Week 2"
            }, 
            {
                "measure": "Number of participants achieving HCV RNA <25 IU/mL at Week 4", 
                "safety_issue": "No", 
                "time_frame": "Week 4"
            }, 
            {
                "measure": "Number of participants achieving HCV RNA <25 IU/mL at Week 12", 
                "safety_issue": "No", 
                "time_frame": "Week 12"
            }, 
            {
                "measure": "Number of participants achieving HCV RNA <25 IU/mL at Week 24", 
                "safety_issue": "No", 
                "time_frame": "Week 24"
            }, 
            {
                "measure": "Number of subjects achieving SVR4", 
                "safety_issue": "No", 
                "time_frame": "Up to Week 28"
            }, 
            {
                "measure": "Number of subjects achieving SVR24", 
                "safety_issue": "No", 
                "time_frame": "Up to Week 48"
            }, 
            {
                "measure": "Number of participants who develop antiviral resistance to MK-5172", 
                "safety_issue": "No", 
                "time_frame": "Up to 48 weeks"
            }
        ], 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}